Abstract
Genome-wide association studies (GWAS) have identified tens of thousands of genetic loci associated with human complex traits and diseases1,2. However, the majority of GWAS were conducted in individuals of European ancestry3. Failure to capture global genetic diversity has limited biological discovery and impeded equitable delivery of genomic knowledge to diverse populations4. Here we report findings from 102,900 individuals across 36 human quantitative traits in the Taiwan Biobank (TWB), a major biobank effort that broadens the population diversity of genetic studies in East Asia (EAS). We identified 979 novel genetic loci, pinpointed novel causal variants through fine-mapping, compared the genetic architecture across TWB, Biobank Japan (BBJ)5–7 and UK Biobank (UKBB)8,9, and demonstrated the utility of cross-phenotype, cross-population polygenic risk scores (PRS) in disease risk prediction. We release all GWAS summary statistics, fine-mapping results, and single nucleotide polymorphism (SNP) weights and TWB-based PRS reference distributions for polygenic prediction (link to appear upon publication) to facilitate within-EAS and cross-population genetic research.
Competing Interest Statement
Chia-Yen Chen is an employee of Biogen. Yen-Chen Anne Feng is an employee of Vertex Pharmaceuticals. Mark J. Daly is a founder of Maze Therapeutics. The remaining authors declare no competing interests.
Funding Statement
Y.F.L. is supported by the National Health Research Institutes (NP-109-PP-09), and the Ministry of Science and Technology (109-2314-B-400-017) of Taiwan. T.G. is supported by NIA K99/R00AG054573. H.H. acknowledges support from NIDDK K01DK114379, NIMH U01MH109539, Brain & Behavior Research Foundation Young Investigator Grant, the Zhengxu and Ying He Foundation, and the Stanley Center for Psychiatric Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Taiwan Biobank obtained ethical approval from the Ethics and Governance Council (EGC) of Taiwan Biobank and the Department of Health and Welfare, Taiwan (Wei-Shu-I-Tzu NO.1010267471). Taiwan Biobank obtained informed consent from all participants. The Taiwan Biobank approved an application for access to and use of the data (TWBR10907-05), and ethical approval for the analysis was obtained from the Institutional Review Board (IRB) of National Health Research Institutes, Taiwan (EC1090402-E).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Publicly available data were downloaded from the following databases: 1000 Genomes Project phase 3 data: https://mathgen.stats.ox.ac.uk/impute/1000GP_Phase3.html; BBJ summary statistics: http://jenger.riken.jp/en/result; UKBB summary statistics: http://www.nealelab.is/uk-biobank (GWAS round 2 was used in this study).
